These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 21476823)
21. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance? Vogt L; Kocks MJ; Laverman GD; Navis G Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515 [TBL] [Abstract][Full Text] [Related]
22. Angiotensin-I converting enzyme inhibition: clinical effects in chronic renal disease. de Jong PE; Heeg JE; Apperloo AJ; de Zeeuw D Am J Kidney Dis; 1991 May; 17(5 Suppl 1):85-8. PubMed ID: 2024682 [No Abstract] [Full Text] [Related]
23. Angiotensin converting enzyme inhibitor-induced renal dysfunction: recommendations for prevention. Cooke HM; De Besse A Int J Clin Pharmacol Ther; 1994 Feb; 32(2):65-70. PubMed ID: 8004361 [TBL] [Abstract][Full Text] [Related]
24. Economic evaluation of benazepril in chronic renal insufficiency. van Hout BA; Simeon GP; McDonnell J; Mann JF Kidney Int Suppl; 1997 Dec; 63():S159-62. PubMed ID: 9407447 [TBL] [Abstract][Full Text] [Related]
26. The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors. Sica DA J Renin Angiotensin Aldosterone Syst; 2002 Jun; 3(2):66-71. PubMed ID: 12228845 [TBL] [Abstract][Full Text] [Related]
27. Failure to practice evidence-based medicine: why do physicians not treat patients with heart failure with angiotensin-converting enzyme inhibitors? McMurray JJ Eur Heart J; 1998 Oct; 19 Suppl L():L15-21. PubMed ID: 9821004 [TBL] [Abstract][Full Text] [Related]
28. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. Schneeweiss S; Walker AM; Glynn RJ; Maclure M; Dormuth C; Soumerai SB N Engl J Med; 2002 Mar; 346(11):822-9. PubMed ID: 11893794 [TBL] [Abstract][Full Text] [Related]
29. Antihypertensive therapy in the presence of proteinuria. Sarafidis PA; Khosla N; Bakris GL Am J Kidney Dis; 2007 Jan; 49(1):12-26. PubMed ID: 17185142 [TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in The Netherlands--a Markov model. Adarkwah CC; Gandjour A; Akkerman M; Evers SM PLoS One; 2011; 6(10):e26139. PubMed ID: 22022539 [TBL] [Abstract][Full Text] [Related]
31. Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal disease. Gansevoort RT; de Zeeuw D; de Jong PE Am J Kidney Dis; 1993 Jul; 22(1):202-6. PubMed ID: 8322784 [TBL] [Abstract][Full Text] [Related]
32. Summaries for patients. The cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for patients with diabetes. Ann Intern Med; 2005 Jul; 143(2):I21. PubMed ID: 16027445 [No Abstract] [Full Text] [Related]
33. The COOPERATE trial. Vogt L; Laverman GD; de Zeeuw D; Navis G Lancet; 2003 Mar; 361(9362):1055-6. PubMed ID: 12660079 [No Abstract] [Full Text] [Related]
34. [Pharmacoeconomical aspects of the use of angiotensin converting enzyme inhibitors in clinical practice (lisinopril use)]. Rudakova AV Kardiologiia; 2003; 43(11):86-92. PubMed ID: 14989248 [No Abstract] [Full Text] [Related]
36. Effect of angiotensin-converting enzyme inhibitors on progression of nondiabetic renal disease. Jafar TH; Schmid CH; Levey AS Ann Intern Med; 2002 Aug; 137(4):298-9. PubMed ID: 12186531 [No Abstract] [Full Text] [Related]
37. Use of angiotensin-converting enzyme inhibitors in patients with diabetic and nondiabetic chronic renal diseases: a need for reassessment. Jaichenko J; Fudin R; Shostak A; Gotloib L Nephron; 1998 Nov; 80(3):367-8. PubMed ID: 9807055 [No Abstract] [Full Text] [Related]
38. ACE inhibitors: back to prime time? Gupta M; Verma S; Mancini GB Heart; 2007 Sep; 93(9):1015-6. PubMed ID: 17699166 [No Abstract] [Full Text] [Related]
39. Targeting the renin-angiotensin system in patients with renal disease. Devonald MA; Karet FE J R Soc Med; 2002 Aug; 95(8):391-7. PubMed ID: 12151488 [No Abstract] [Full Text] [Related]
40. The effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a pooled analysis of individual-patient data from 11 randomized, controlled trials. Schrier RW; Estacio RO Ann Intern Med; 2001 Jul; 135(2):138-9. PubMed ID: 11453714 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]